Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase...

بواسطة Hagop Kantarjian, Ricardo Pasquini, Vincent Lévy, Saengsuree Jootar, Jerzy Holowiecki, Nelson Hamerschlak, Timothy Hughes, Eric Bleickardt, David Dejardin, Jorge Cortes, Neil P. Shah
منشور في 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

بواسطة Giuseppe Saglio, Dong Wook Kim, Surapol Issaragrisil, Philipp Le Coutre, Gabriel Etienne, Clarisse Lobo, Ricardo Pasquini, Richard E. Clark, Andreas Hochhaus, Timothy P. Hughes, Neil Gallagher, Albert Hoenekopp, Mei Dong, Ariful Haque, Richard A. Larson, Hagop M. Kantarjian
منشور في 2018

Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021),...

بواسطة Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson, Dong Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Etienne, Carla Boquimpani, Ricardo Pasquini, Richard E. Clark, Viviane Dubruille, Ian W. Flinn, Slawomira Kyrcz-Krzemien, Ewa Medras, Maria Zanichelli, Israel Bendit, Silvia Cacciatore, Ksenia Titorenko, Paola Aimone, Giuseppe Saglio, Andreas Hochhaus
منشور في 2022

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

بواسطة Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson, Dong Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Etienne, Carla Boquimpani, Ricardo Pasquini, Richard E. Clark, Viviane Dubruille, Ian W. Flinn, Slawomira Kyrcz-Krzemien, Ewa Medras, Maria Zanichelli, Israel Bendit, Silvia Cacciatore, Ksenia Titorenko, Paola Aimone, Giuseppe Saglio, Andreas Hochhaus
منشور في 2022